Logo

American Heart Association

  108
  0


Final ID: Th0057

Itaconate reduces foam cell formation through alkylating CD36

Abstract Body: Background: Dysregulated lipid metabolism results in the formation of lipid-dense macrophages, termed foam cells. Foam cell formation and accumulation in the artery is a key process in atherosclerosis development. The scavenger receptor CD36 is the main responsible receptor in foam cell formation by mediating oxidized LDL (oxLDL) uptake. Itaconate, a byproduct of tricarboxylic acids cycle, possesses various functions such as anti-inflammation and anti-oxidants through protein alkylation, a posttranslational modification. Recently, it has been reported that the itaconate derivative, 4-octyl-itaconate (4-OI) alleviates atherosclerosis and reduces foam cell formation in vivo. However, the mechanism of how 4-OI reduces macrophage lipid accumulation is unknown.
Hypothesis: We hypothesize that 4-OI modifies CD36 and reduces foam cell formation by inhibiting CD36-mediated oxLDL uptake.
Methods: Mouse peritoneal macrophages or human monocyte-derived macrophages were treated with oxLDL and 4-OI. Foam cell formation was evaluated by Oil red O staining and cholesterol assay. Quantitative RT-PCR and Western blot were used to analyze CD36 expression. Surface CD36 expression and oxLDL binding and uptake assay were observed by flow cytometry. To detect modified CD36 protein, itaconate-alkyne (Italk) probe was applied to macrophages and followed by a pull-down assay and Western blot.
Results: After 4-OI 24h treatment, foam cell numbers and cholesterol content induced by oxLDL were reduced by half both in mouse peritoneal macrophages and human monocyte-derived macrophages (n=4). After 4-OI treatment with WT macrophages, oxLDL binding to the cell surface reduced by 25% and oxLDL uptake by 40%, despite no change in surface CD36 (n=6). However, 4-OI didn't change oxLDL binding and uptake in CD36 knockout cells. Finally, using Italk probe, we showed that 4-OI alkylated macrophage CD36 (n=3).
Conclusion: We identify a novel regulatory mechanism that 4-OI inhibits foam cell formation by alkylating CD36 protein and reducing oxLDL uptake in macrophages. These findings may have new therapeutic implications on atherosclerosis.
  • Wang, Yaxin  ( Versiti Blood Research Institute , Milwaukee , American Samoa )
  • Chen, Vaya  ( Versiti Blood Research Institute , Milwaukee , American Samoa )
  • Vick, Lance  ( Versiti Blood Research Institute , Milwaukee , American Samoa )
  • Chang, Jackie  ( Versiti Blood Research Institute , Milwaukee , American Samoa )
  • Chen, Yiliang  ( Versiti Blood Research Institute , Milwaukee , American Samoa )
  • Author Disclosures:
    Yaxin Wang: DO NOT have relevant financial relationships | Vaya Chen: No Answer | Lance Vick: DO NOT have relevant financial relationships | Jackie Chang: No Answer | Yiliang Chen: No Answer
Meeting Info:
Session Info:

15. Poster Session 3 & Reception

Thursday, 04/24/2025 , 05:00PM - 07:00PM

Poster

More abstracts on this topic:
A human cardiomyocyte model of CD36 haploinsufficiency uncovers fatty acid oxidation deficits driving dilated cardiomyopathy

Al Sayed Zeina, Klattenhoff Carla, Aragam Krishna, Ellinor Patrick, Willcox Jon, Zheng Alice, Koledova Vera, Srivastava Salil, Yin Xiaofei, Chaffin Mark, Rigaud Vagner, Kovacs-bogdan Erika

A Single-Dose of a Novel CasX-Editor Lowers APOC3 Levels In Vivo

Karanth Santhosh, Ripley-phipps Sterling, Miller Katherine, Su Ali, Mrak Anna, Karmarkar Maitreyee, Eggers Michelle, Bardai Farah, Narsineni Lokesh, Li Yuexuan, Langner Heera, Bucher Simon, Szulwach Keith, Goh Natalie, Mok Amanda, Reimer Kirsten, Oakes Benjamin, Khakoo Aarif, Mirotsou Maria, Smekalova Elena, Saraya Jennifer, Stein Shannon, Sato Anna, Bale Shyamsundhar, Krupa Oleh, Mauriello Anthony

You have to be authorized to contact abstract author. Please, Login
Not Available